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Edited by Shou-Wei DingAbstract In recent years, we have witnessed the discovery of a
new mechanism of gene regulation called RNA interference
(RNAi), which has revitalized interest in the development of nu-
cleic acid-based technologies for therapeutic gene suppression.
This review focuses on the potential therapeutic use of RNAi, dis-
cussing the theoretical advantages of RNAi-based therapeutics
over previous technologies as well as the challenges involved in
developing RNAi for clinical use. Also reviewed, are the in vivo
proof-of principle experiments that provide the preclinical justiﬁ-
cation for the continued development of RNAi-based therapeutics.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The pharmaceutical industry has an ongoing interest in
developing technologies for therapeutic gene suppression. Pre-
vious eﬀorts focused on sequence-speciﬁc RNA knockdown
technologies such as antisense oligonucleotides and ribozymes.
While some success has been achieved with these drug plat-
forms [1], technical issues regarding delivery, stability, oﬀ-target
eﬀects, and eﬀective target sequence selection have slowed
the development of eﬃcacious clinical drugs. In recent years,
however, we have witnessed the discovery of a new mechanism
of gene regulation called RNA interference (RNAi), which has
revitalized interest in the clinical development of nucleic acid-
based gene inhibition approaches. This review focuses on the
potential therapeutic use of RNAi. After a brief introduction
to RNAi, we discuss the theoretical advantages of RNAi-based
therapeutics over previous technologies and then temper that
optimism with a discussion of the challenges involved in devel-
oping RNAi for clinical use. Finally, we review proof-of prin-
ciple experiments that have demonstrated the clinical potential
of RNAi, highlighting some of the in vivo successes that pro-
vide the preclinical justiﬁcation for the continued development
of RNAi-based therapeutics.
RNAi is a naturally occurring biological process that is highly
conserved among multicellular organisms diverse as plants,
worms, yeast, and humans. It refers to a two-part intracellular
pathway in which precursor double-stranded RNA molecules
present in the cell are ﬁrst processed by the dicer endonuclease
into short 21-23 nucleotide fragments containing 2 nucleotide*Fax: +1 858 784 2960.
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RNAs, called short interfering RNAs (siRNAs), then become
incorporated into an RNA-inducing silencing protein complex
(RISC) in which one strand of the unwound siRNA acts as a
guide sequence to target the cleavage of homologous RNAs
[2–4]. In plants, RNAi plays a role in cellular defense, protecting
the cell from inappropriate expression of repetitive sequences,
transposable elements, and virus infections (reviewed in [5]).
In addition to evidence that similar defense functions may still
be active in mammalian cells [6,7], an increasing number of
short RNA molecules are being found encoded in the mamma-
lian genome. These endogenous RNAs, or microRNAs (miR-
NAs), are also processed by dicer into siRNA eﬀectors, and
are proving to regulate the expression of genes involved in a
variety of cellular processes such as proliferation, apoptosis,
and diﬀerentiation (reviewed in [8–10]). Importantly, when siR-
NA molecules are chemically synthesized and exogenously
introduced into mammalian cells, they become incorporated
into the cellular RISC complex and mediate the degradation
of RNAs to which they are homologous [2–4].
The ability to tap into this native pathway has been recog-
nized as one the most exciting biotechnology advances in the
last decade. Indeed, RNAi has revolutionized biology research,
including drug target discovery, by allowing for rapid identiﬁ-
cation and validation of gene function. While this alone justi-
ﬁes RNAi being named the Breakthrough of the Year in 2002
by Science magazine, many are hopeful that the greatest con-
tribution of RNAi is yet to come, that it will serve as a means
of sequence-speciﬁc therapeutics against a wide range of dis-
eases. As such, several companies are focusing on the develop-
ment of RNAi-based therapeutics (Table 1) [11].2. Advantages of RNAi therapeutics
2.1. Speciﬁcity
One of the potential advantages of sequence-based gene sup-
pression technologies is the ability to design precisely targeted
therapeutics for almost any gene, regardless of the function of
the gene product, whether that function is clearly deﬁned, and
in the absence of any protein structure information. Particu-
larly in the ﬁelds of oncology and genetic neurological disor-
ders where disease is often caused by a dominant mutation
in a single allele, this would oﬀer the opportunity to selectively
inhibit expression of only the defective gene. However, being
able to identify an eﬀective target sequence in which a single
polymorphism can be distinguished is not trivial. Impressively,
although our knowledge of optimal siRNA target selection is
still limited, RNAi activity is speciﬁc enough that allele-speciﬁcblished by Elsevier B.V. All rights reserved.
Table 1
Companies developing RNAi therapeutics
Company name Primary areas of interest
Acuity Pharmaceuticals AMD; diabetic retinopathy
AGY Therapeutics RNAi in neurons and glial cells
Alnylam Pharmaceuticals Inc. AMD; Parkinsons disease, respiratory syncytial virus; cystic ﬁbrosis; inﬂuenza; spinal cord injury
Atugen AG Metabolic disease; cancer ocular disease; skin disease
Benitec Australia Limited Hepatitis C virus; HIV/AIDS; cancer; diabetes/obesity
Calando Pharmaceuticals Nanoparticle technology
Cytrx Corporation Diabetes/obesity; ALS; cytomegalovirus retinitis
Devgen Diabetes/obesity; arrhythmia
Genesis R&D Allergy
Genta Incorporated Cancer
International Therapeutics HIV; Hepatitis B virus
Intradigm Corporation Cancer; SARS; arthritis
Nucleonics, Inc. Hepatitis B Virus; Hepatitis C virus
Sirna Therapeutics, Inc. AMD; Hepatitis C virus; asthma; diabetes; cancer Huntingtons disease; hearing loss
AMD, age-related macular degeneration; SARS, severe acute respiratory syndrome coronavirus; ALS, amyotrophic lateral sclerosis.
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cancer and neurological targets [12–17].
2.2. Potency
While it can be diﬃcult to directly compare the eﬃciency of
gene suppression technologies due to diﬀerences in the rules for
optimal design and target sequence selection, several studies
have supported the conclusion that RNAi-mediated inhibition
is more potent than that achieved with antisense oligonucleo-
tides even in cases where site selection was optimized for anti-
sense eﬀectiveness (reviewed in [18]). This is also empirically
evident by the remarkable speed at which RNAi techniques
have been implemented in scientiﬁc research, and the number
of successful RNAi-based experiments already published. It
is speculated that this advantage is derived from the fact that
RNAi is an innate biological response, and hence represents
a more natural strategy for manipulating gene expression. In
any event, it means that physiologically beneﬁcial silencing
can be achieved with lower concentrations of eﬀector mole-
cules [19–23] (reviewed in [18,24]).2.3. Versatility
Perhaps due to its superior potency, it is also relatively easy to
identify eﬀective RNAi target sites. Although the rules for opti-
mal RNAi eﬀectiveness are still being determined, when basic
parameters regarding CG content and the composition of the
3 0 overhangs are met, then a high percentage of potential targets
screened usually prove to be functional [21,23,25–28]. On the
other hand, it is signiﬁcantly more diﬃcult to identify eﬃcient
antisenseoligonucleotide target sequences [21,23,29] (Uprichard,
unpublished data) and ribozyme target selection is limited by the
availability of particular sequence motifs required for cleavage
[30]. The versatility and ease with which RNAi-mediated inhibi-
tion canbe inducedmeans thatmultiple sequenceswithinan indi-
vidual gene, or a group of genes, can be targeted simultaneously,
more readily providing the beneﬁt of combination therapy.3. Challenges of RNAi therapeutics
3.1. Delivery
The problem of delivery is not unique to RNAi therapeutics,
but it is by far the major obstacle to the clinical use of RNAi-
based drugs.3.1.1. RNAi eﬀectors. RNAi eﬀectors can be delivered to
cells using two diﬀerent approaches. In one case, siRNAs are
synthesized in the laboratory to be delivered as a ‘‘drug’’.
The second option is a gene therapy approach in which
DNA encoding short hairpin RNA (shRNA) expression cas-
settes are delivered to cells to allow for intracellular expression
of shRNAs, which are then processed into active siRNAs by
the host cell [31,32]. The potential advantages of the latter
DNA approach include the inherently higher stability of tran-
siently delivered plasmid DNAs and the fact that this strategy
consists of an intracellular ampliﬁcation step in which large
amounts of shRNAs can be synthesized from each individual
template. Additionally, it is also possible to deliver DNA
expression vectors stably, either by integration into the genome
or in self-replicating episomal form, which theoretically could
allow for constitutive expression of the shRNA cassette.
3.1.2. Local delivery. Based on the precedent of successful
local administration of antisense drugs to the eye [33], initial
clinical trials for RNAi-based treatment of age-related macular
degeneration are all using local injection of siRNAs directly
into the eye [34]. Other promising local routes are intranasal
administration for pulmonary delivery [35–37] and direct deliv-
ery into the central nervous system [38–40]. Nonetheless, for
RNAi therapeutics to overcome the impediments of the gene
silencing technologies that came before it, eﬀective systemic
delivery and subsequent targeting to the correct cells must be
achieved.
3.1.3. Systemic delivery. Optimizing systemic delivery re-
quires stabilization of the siRNA, targeting of the eﬀector to
the correct tissue, and facilitation of cellular uptake. Thus
far, approaches to improve stability and cellular uptake of
siRNA drugs include many of the same strategies employed
for antisense oligonucleotides such as direct chemical alter-
ation of the nucleic acid [41,42] and various methods of pack-
aging the eﬀector into protective particles [41,43–47]. To target
the eﬀector to particular cell types, diﬀerent ligands [48–50]
and antibodies [51] are being incorporated into/conjugated to
the RNAi eﬀector, but continued work is needed to achieve
the eﬃciency required.
Notably, the use of viral vectors may be useful for systemic
delivery of RNAi eﬀectors. Unfortunately, although viral vec-
tors can provide the excellent tissue-speciﬁc tropism and trans-
duction eﬃciency needed for clinical delivery, each type of
viral vector brings with it a unique set of risks and safety con-
cerns (reviewed in [52]). Despite setbacks encountered in past
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of RNAi therapeutics are compelling and in some cases may
outweigh the risks. Hence, both lentivirus and adeno-associ-
ated virus (AAV) vectors are being considered for clinical
delivery of shRNAs [53,54].
3.2. Safety
The aim of any therapeutic is to maximize the ratio of de-
sired eﬀects to undesired eﬀects. In some cases, such as chemo-
therapy, interferon treatment, and highly active antiretroviral
treatment, the ratio is not ideal and a signiﬁcant degree of tox-
icity is associated with treatment. While RNAi has the capacity
to provide better gene targeting speciﬁcity, the exposure of
cells to any exogenous molecule (siRNA or delivery agent)
has the potential to perturb normal cellular functions and
needs to be carefully controlled.
3.2.1. Oﬀ-target eﬀects. While speciﬁcity is one of the great-
est advantages oﬀered by RNAi, oﬀ-target eﬀects are still a po-
tential problem, particularly because the parameters that
determine the minimum level of homology required for
siRNAs to mediate inhibition of a gene are not yet known.
Depending on the sequence of an siRNA, as few as 11 base
pairs of homology with a single-stranded RNA has been found
to result in inhibition [55]. Importantly, the wealth of search-
able genetic information now available provides a valuable
tool that can be used to try to avoid inadvertent oﬀ-target
homology, but rigorous empirical screening of all potential
siRNA eﬀectors will continue to be necessary to limit oﬀ-target
eﬀects.
3.2.2. Non-speciﬁc eﬀects. The issue of non-speciﬁc toxicity
is twofold for RNAi because both the delivery vehicle and the
siRNA eﬀector itself may elicit unexpected cellular responses.
Firstly, it has been found that some cationic liposomes used
to deliver siRNAs might induce or potentiate interferon re-
sponses [56,57]. Likewise, any viral vector that might be used
to transport shRNA expression cassettes into cells could stim-
ulate an undesired vector-speciﬁc immune response. Secondly,
the nature of siRNA eﬀectors themselves may trigger the
induction of the double-stranded RNA cellular defense mech-
anism. Although interferon induction might be beneﬁcial for
therapy in some instances, uncontrolled induction of this in-
nate defense mechanism can be cytotoxic, and is therefore a
concern. Initial gene expression proﬁling by diﬀerent laborato-
ries provided conﬂicting results regarding whether or not inter-
feron is induced in response to siRNAs [55,58–61]. Recent
studies, however, have started to systematically analyze these
diﬀerences revealing that while certain siRNAs do induce an
interferon response, others do not (reviewed in [62]). For
example, Hornung et al. [63] have identiﬁed a 9 base pair ‘‘dan-
ger motif,’’ which in the context of an siRNA eﬀector induces
interferon signaling. Additionally, the structure of introduced
siRNA molecules can dictate whether or not interferons are in-
duced, as Kim et al. [64] have reported that the presence of a 5 0
phosphate can trigger interferon induction. Consequently,
careful design and screening of each candidate siRNA and
delivery vehicle will be necessary to try to identify and mini-
mize all potential adverse eﬀects.
3.2.3. Saturation of RNAi machinery. While the ease and
eﬃciency of siRNA inhibition may be derived from the fact
that these exogenously added molecules are usurping a natural
cellular pathway, a growing safety concern is that this could
interfere with the regulatory functions of endogenous miRNAs,which are known to share some of the same processing
machinery [65]. Evidence suggests that when excess siRNAs
are delivered to mammalian cells, the intracellular RNAi pro-
cessing machinery can become saturated. This conclusion is
drawn from studies that demonstrate competition between
co-delivered siRNAs targeting two diﬀerent genes [36] and
inhibition of siRNA function by a co-delivered scrambled
siRNA [66,67]. While we are just beginning to appreciate
the diverse roles miRNAs play in mammalian cells, accumu-
lating data indicates that they are involved in many critical as-
pects of gene regulation (reviewed in [8–10]). Furthermore,
alterations in the expression of miRNAs or their processing
machinery have recently been implicated in several neurologi-
cal diseases [68–70] and cancers [70–77]. In some instances
over expression of miRNAs has been found to be oncogenic
[73,76,77], but in other cases reduced miRNA expression is
observed in cancer cells [71,74,75]. It will therefore be impor-
tant to assess the long-term consequences of RNAi therapy, in
order to determine if miRNA functions are negatively af-
fected. To overcome this problem, it might be necessary to
analyze diﬀerent doses of siRNAs to determine the maximum
capacity of the intracellular siRNA processing machinery in
diﬀerent cell types.
3.3. Eﬃcacy
A wide variety of issues will ultimately determine the eﬃcacy
of particular RNAi-based therapeutics.
3.3.1. Resistance. Ironically, the exceptional sequence-spec-
iﬁcity of RNAi is also viewed as one of its potential weak-
nesses. This problem is often cited when discussing the use of
RNAi as an antiviral agent as it has been demonstrated that
both RNA and DNA viruses can rapidly generate RNAi es-
cape mutations [78–82]. This problem will probably necessitate
the use of RNAi in combination therapy approaches, including
multiple RNAi target sequences and/or other synergistic anti-
virals, such as small molecule inhibitors. Another possible issue
regarding viral resistance is the discovery that analogous to
plant viruses (reviewed in [5]), some mammalian viruses, such
as Nodamura virus and human immunodeﬁciency virus (HIV),
encode genes that may interfere with RNAi silencing [6,7].
Notably however, the eﬀectiveness of these virally encoded
genes in preventing therapeutic RNAi inhibition remains to
be determined. Resistance of particular RNAs to RNAi-med-
iated degradation has also been observed in cases where acces-
sibility of the target sequence was restricted. For cellular
mRNAs, the structure of the target RNA has been found to
aﬀect silencing eﬃciency [83,84]. For viral RNAs, resistance
can also be related to intracellular location and/or nucleocap-
sid association of genomic RNA molecules [85–87].
Resistance may also be a fundamental problem for the treat-
ment of some cancers. As altered expression of miRNAs and
their processing enzyme, dicer, have recently been found to
be associated with diﬀerent types of cancer [70–77], it is possi-
ble that the processing machinery required for siRNA activity
is not functionally normal in some tumor cells. Hence, depend-
ing on the nature of the oncogenic defect, it is possible that
therapeutically delivered siRNAs may not be as eﬀective in
these cells. On a positive note, preliminary studies have dem-
onstrated the eﬀectiveness of siRNAs in multiple cancer mod-
els. Yet, the role miRNAs play in oncogenesis and how this
might impact siRNA processing is an area that needs to be fur-
ther investigated.
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than other gene silencing methods [19–23] (reviewed in [18,24]),
when designing RNAi-based therapeutics it is necessary to
consider the quantitative limitations inherent in this technol-
ogy. Speciﬁcally, RNAi knocks-down gene expression, but
generally does not eliminate it. For some conditions, partial
down regulation of a pathogenic gene appears to be suﬃcient
to produce clinically relevant improvement, however this is not
‘‘cure’’. In the case of genetic diseases, a ‘‘cure’’ is not necessar-
ily expected, but for other conditions such as cancer or infec-
tious disease, the ideal goal of therapy would be to rid the
patient of the disease. This limitation has been illustrated in
several xenograph mouse tumor models in which siRNA
silencing of oncogenes in vivo has been shown to slow the rate
of tumor progression and prolong survival, but the tumors
were not cleared [88,89]. Hence, in many cases, RNAi treat-
ment strategies may only be eﬀective if designed in the context
of a synergistic combinatorial therapy approach.
3.3.3. Duration. Also related to eﬃcacy is the duration of
the therapeutic eﬀect. When delivered as a drug, siRNAs and
shRNA-expressing DNA templates function transiently.
When transfected into cells in culture, the inhibitory eﬀect
usually peaks at day 2 post-transfection and fades thereafter.
Alterations in siRNA stability (see below) may prolong this
eﬀect, but in the absence of any endogenous RNAi mecha-
nism for ampliﬁcation or spread in mammalian cells, the
activity of these delivered nucleic acids is expected to remain
transient in nature. If the delivered siRNAs are part of an
acute curative treatment, then transient activity might be suf-
ﬁcient, but in cases where RNAi suppression is part of a
long-term treatment protocol it will require frequent dosing
probably at signiﬁcant cost. Notably, the desire to developTable 2
Inhibition of viral gene expression and replication by RNAi
Virus In vitro In vivo
Reference Model system Delivery
Vehicle
West Nile Virus [95] Mouse infection None
Hepatitis C Virus [97] Reporter transcript None
Coxsakievirus B3 – Mouse infection None
RSVa [87] Mouse infection None/TransIT
Parainﬂuenza – Mouse infection None/TransIT
Inﬂuenza [95,100] Mouse infection PEI-complex
Mouse infection Oligofectamin
Hepatitis B virus [103–105] Hydrodynamic None
Hydrodynamic None
Transgenic Mouse Adenovirus
Hydrodynamic Stabilized
SARS-CoVc [108]
Rhinovirus [109]
Poliovirus [110]
HIVd [111]
Papillomomavirus [112]
Cytomegalovirus [113]
hd, hydrodynamic injection; i.v., intravenous injection; i.n., intranasal admin
aRSV, respiratory syncytial virus.
bTransgenic mice constitutively express and replicate HBV, therefore this is
time of viral delivery.
cSARS-CoV, severe-acute respiratory syndrome-coronavirus.
dHIV, human immunodeﬁciency virus.RNAi-based therapeutics for chronic conditions, such as ge-
netic defects, is one of the main motivations for developing
gene therapy delivery techniques, which presumably would al-
low for constitutive intracellular expression of the therapeutic
shRNA.
3.3.4. Stability. Although some data indicate that siRNAs
are more stable in serum and mammalian cells than antisense
oligonucleotides and ribozymes [19], multiple approaches are
being investigated to alter the pharmacokinetic properties of
siRNAs to increase their half-life in vivo. Not only are protec-
tive vehicles, such as liposomes, being designed to escort and
target intact siRNA eﬀectors for cellular uptake, but chemical
modiﬁcation of the siRNAs is also being investigated as a
means of directly stabilizing the molecules. Importantly, sev-
eral groups have shown that inhibition of gene expression by
siRNAs is compatible with a broad spectrum of chemical mod-
iﬁcations [26,42,90–93]. Most recently, Morrissey et al. demon-
strated that a combination of direct modiﬁcations improved
stability, and thus in vivo eﬃcacy of intravenously adminis-
tered siRNAs [40]. However, as determined by the authors, less
than 1% of the injected siRNA reached their target organ indi-
cating that modiﬁcations to improve targeting and/or cellular
uptake will also be necessary.
Importantly, despite these challenges, a wide variety of dis-
ease-relevant genes have been speciﬁcally inhibited with
siRNAs and shRNAs in vitro and in small animal models
(Tables 2–4). Additionally, planned and ongoing clinical trials
will soon provide valuable information regarding eﬃcacy,
dosing, delivery, and safety, which should be useful in the con-
tinued advancement of RNAi-based drugs and in the analysis
of issues such as compliance which factor into the success of
any therapeutic regimen.Reference
Route Time of treatment
hd Prophylactic (at 4 h) [96]
hd Co-transfection [98]
hd Therapeutic (at 6 h) [99]
i.n. Prophylactic (at 4 h) [36]
Therapeutic (at 1–3 days)
i.n. Prophylactic (at 4 h) [36]
lentivirus i.v./i.n. Prophylactic (at 12 h) [101]
Therapeutic (at 5 h)
e hd/i.n. Prophylactic (at 24 h) [102]
hd Co-transfection [106]
hd Co-transfection [107]
i.v. Therapeuticb [25]
i.v. Therapeutic (at 3 days) [42]
istration.
a model of chronic HBV, therefore time of treatment is not related to
Table 3
Therapeutic targets of RNAi tested in vivo
Field Disease Target Route Vehicle References
Neurological Amyotrophic lateral sclerosis SOD1 i.m. Lentivirus [126]
SOD1 Intraspinal Lentivirus [127]
Spinocerebellar ataxia Ataxin1 i.c. AAV [40]
Huntingtons disease Huntingtin i.c. AAV [128]
Neuropathic pain P2X3 cation channel Intrathecal None [39]
Ocular Inﬂammation in eye TGFb RII Local None [129]
AMD VEGF Local Transit TKO [130]
Herpetic stromal keratitis VEGF/R i.v. Ligand directed [131]
Hearing Autosomal dominant Gap junction b2 Local Liposome [132]
Inﬂammation Rheumatoid arthritis TNFa Local None [133]
Sepsis TNFa i.p. None [44]
Apoptosis Acute liver failure Fas hd None [134]
Caspase 8 hd/p.v. None [135]
Liver ischemia/reperfusion Caspase 8/3 hd 10%lipiodol [136]
Renal ischemia/reperfusion Fas hd None [137]
Lung ischemia/reperfusion Heme oxygenase1 i.n. None [37]
Metabolism Obesity AGRP i.c None [38]
Cholestrol ApoB i.v. Modiﬁed [41]
hd, hydrodynamic injection; i.v., intravenous; i.n., intranasal; i.c., intracranial; i.m., intramuscular; AAV, adeno-associated virus; AMD, age-related
macular degeneration; AGRP, agouti related peptide.
Table 4
Anti-cancer RNAi targets tested in vivo
Target Route Vehicle References
Bcl-2 i.v. Liposome [145]
Cxcr4 i.v. None [146]
Focal adhesion kinase i.v. None [147]
EphA2 i.v. None [148]
Polo-like kinase 1 i.v. ATA-treated [149]
Colony-stimulating factor i.t. None [150]
survivin hd DNA [151]
CEACAM6 i.v. None [152]
EGFR i.v. Ligand-targeted [49]
Erbb2/neu (HER2)R i.p. PEI-complex [47]
Skp-2 i.t. Adenovirus [153]
Spingosine-1 phosphate-R i.t. Liposome [154]
RhoA i.t. None [155]
VEGF-R i.v. Ligand-targeted [46]
VEGF i.t./i.v. Atelocollagen [156]
FGF4 i.t. Atelocollagen [157]
i.v., intravenous; i.t., intratumoral; hd, hydrodynamic injection; ATA,
aurintricarboxylic acid; CEACAM6, carcinoembryonic antigen-related
adhesion molecule 6.
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4.1. Viral infection
One of the earliest proposed therapeutic uses of RNAi was
to inhibit viral infection, and several companies developing
RNAi-based therapies have ongoing programs focused on vir-
al targets (Table 1).
Targeting viral RNAs. Many reports have shown that pre-
treatment or co-treatment with virus-speciﬁc siRNAs can be
used to inhibit the expression and/or replication of numerous
viruses in vitro and in vivo (reviewed in [94]) (Table 2). In par-
ticular, investigations into the potential antiviral beneﬁts of
RNAi have focused heavily on HIV (reviewed in [111]) andthe hepatitis viruses (reviewed in [97,114,115]), as currently
available treatment options against these viruses are inade-
quate. Furthermore, the availability of multiple well-deﬁned
HBV mouse models [116,117] has made this virus a popular
target for in vivo proof-of-concept studies. Initial in vivo
hydrodynamic transfection experiments demonstrated that
simultaneous delivery of HBV expression plasmids and
HBV-speciﬁc siRNAs (or shRNA expression vectors) to the
mouse liver can prevent the induction of HBV gene expression
and replication [106,107,118]. To expand on those studies, we
and others have further examined the therapeutic potential of
RNAi for the treatment of chronic HBV infection using mouse
models in which ongoing viral gene expression and replication
are established in the liver prior to siRNA delivery [25,42].
Although it has been shown that some viral RNAs are resis-
tant to silencing [85–87] and some mammalian viruses, like
HIV, may encode proteins that interfere with RNAi activity
[7], in the case of HBV, signiﬁcant inhibition of viral gene
expression and replication was achieved by therapeutic admin-
istration of RNAi eﬀectors in 2 diﬀerent mouse models. Like-
wise, inhibition of inﬂuenza virus [35], coxsackievirus B3 [99],
and respiratory syncytial virus (RSV) [36] infections have been
inhibited by siRNAs delivered after the establishment of infec-
tion in mice.
Targeting host cell genes. Because viruses can rapidly gen-
erate escape mutations when siRNAs are targeted directly to
their genome [78–82,110], another potential RNAi antiviral
strategy is to inhibit the expression of cellular factors that
perpetuate the infection. In particular, HIV cellular recep-
tors, such as CD4 and CCR5, are appealing targets for inhi-
bition as this could signiﬁcantly block initial viral entry into
susceptible cell types [119–123]. Before implementing this
type of indirect inhibition approach, however, it would be
important to determine what other eﬀects might occur as a
result of down regulating the particular host gene in ques-
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against some viruses.
In terms of the potential for viral clearance, RNAi knock
down of viral RNAs alone is unlikely to completely eliminate
viral infection, however, it may still prove to be an eﬀective
antiviral if viral replication and spread can be reduced suﬃ-
ciently to allow the endogenous host immune response to suc-
cessfully combat the infection. For example, in the case of
HBV, even chronically infected patients maintain a virus-
speciﬁc cytotoxic T lymphocyte (CTL) response throughout
the course of infection. Although that immune response is
not strong enough to independently clear the virus, it does con-
tinue to destroy cells expressing HBV antigens meaning that
any cells in which HBV has been silenced would have a sur-
vival advantage and may be selected over time to repopulate
the liver.4.2. Neurological disease
Parkinsons disease, Huntingtons disease (HD), fragile X
syndrome, amyotrophic lateral sclerosis (ALS), and spinobul-
bar muscular atrophy, are just some of the prominent neuro-
logical diseases for which RNAi-based therapies might prove
useful (reviewed in [124,125]) (Table 3). The germane common-
ality among these neurodegenerative disorders is that they re-
sult from dominant mutations in a single allele. Hence, in all
cases, the sequence speciﬁcity oﬀered by RNAi may provide
a means of inhibiting expression of the mutant target gene
while allowing the essential wild type allele to be expressed.
Recent examples of the ability of siRNAs to distinguish sin-
gle nucleotide diﬀerences between wildtype and mutant RNAs
have been demonstrated in models of ALS, which is a lethal
motor neuron degenerative disease for which there is currently
no treatment [138]. ALS results from single nucleotide muta-
tions in the gene encoding Cu/Zn superoxide dismutase
(SOD1). In 2003, Ding et al. [14] reported that siRNAs and
PolIII-driven shRNAs could be designed to selectively silence
a dominant mutant ALS allele. More recently, two reports
have conﬁrmed the eﬀectiveness of this approach in a trans-
genic SOD1(G93A) mouse model of ALS [126,127]. In both
studies, lentiviral vectors were used to deliver shRNAs speciﬁc
for the mutant SOD1. Both intramuscular and intrasplenic
injection resulted in reduction of mutant SOD1(G93A) expres-
sion leading to a prolonged survival of motor neurons, a delay
in the onset of ALS symptoms, and an increase in lifespan.
Although the in vivo delivered shRNAs in these experiments
were speciﬁc for the human transgene due to sequence diﬀer-
ences between the mouse and human genes, the previous study
by Ding et al., demonstrate the feasibility of distinguishing
more closely related human SOD1 alleles. In terms of general
clinical application however, the bigger issue may be that ALS
can be caused by more than 100 distinct SOD1 mutations. To
address this issue, Xia et al. [139], have tested a ‘‘replacement
RNAi strategy’’ in which they target inhibition of all mutant
and wildtype forms of SOD1, while simultaneously delivering
a functional SOD1 gene that is resistant to their siRNAs due
to the presence of a silent mutation. If gene therapy ap-
proaches, such as lentivirus, are developed for the delivery
SOD1-specifc siRNA, it should also be possible to use this type
of replacement RNAi strategy.
Another class of dominant negative mutant targets is found
in at least 8 progressive neurogenerative disorders, which in-clude HD and spinocerebellar ataxia (SCA1). These diseases
are caused by polyglutamine expansions in which CAG trinu-
cleotide repeats are found in the mutant allele. In disease mod-
els of both HD and SCA1 the mutant protein has been shown
to be toxic to neurons and that repression of the mutant gene is
clinically beneﬁcial in reversing motor dysfunction [140–142].
Two recent reports have used AAV vectors to express dis-
ease-speciﬁc shRNAs in the brain of transgenic mice that model
HD [128] and SCA1 [40]. In both cases, expression of the mu-
tant gene was reduced resulting in an improvement in behavior
and neuropathological abnormalities. One caveat the authors
acknowledge in both studies is that due to the nature of the
transgenic model, the in vivo delivered shRNAs were by de-
fault speciﬁc for the mutant human transgene based on se-
quence diﬀerences between the mouse and human genes.
However once again, previous in vitro studies have demon-
strated that allele-speciﬁc targeting of genes containing poly-
glutamine expansions is possible [15]. Interestingly however,
while it was determined that siRNA targets within the CAG
repeat region do not necessarily result in allele-speciﬁc inhibi-
tion, the authors demonstrated that siRNAs could be designed
to distinguish these alleles based on associated single-nucleo-
tide polymorphisms (SNPs), which may or may not function-
ally contribute to the disease phenotype [15].
In addition to targeting dominant mutant alleles, RNAi-
based approaches could also prove useful for the treatment
of other forms of neurological disease in which inhibition of
speciﬁc processing/regulatory pathways is required. For exam-
ple, Alzheimers is caused by an increase in b-amyloid produc-
tion, which requires cleavage by b-secretase (BACE1), an
enzyme that is up regulated in the brain of Alzheimers pa-
tients. Hence, siRNAs targeting the downregulation of BACE1
may be able to halt the progression of Alzheimers. As proof of
concept, Kao et al. have used RNAi to inhibit BACE1 expres-
sion in primary mouse cortical neurons and observed the ex-
pected decrease in b-amyloid production [143]. Similarly, as
more is learned about the molecular mechanisms that mediate
neurotoxicity in acute adverse neurological events, such as
stroke and spinal cord injury, it is likely that targets can be
identiﬁed for minimizing the events that lead to neuron dam-
age and facilitating restorative processes.4.3. Oncology
While conventional chemotherapy has proven to be an eﬀec-
tive means of killing cancerous cells, it lacks the selectivity re-
quired to distinguish tumor cells from normal cells resulting in
a signiﬁcant degree of collateral cell death. Therefore, a ther-
apy that could be targeted speciﬁcally to cancer cells would
provide a more attractive treatment option. While eﬃcient
delivery and targeting are ongoing issues for the development
of RNAi-based drugs, the potential utility of RNAi in inhibit-
ing cancer cell proliferation has recently been demonstrated in
many in vitro as well as in vivo studies (Table 4) (reviewed in
[144]).
Direct targeting of oncogenes. Again, the ability of siRNAs
to discriminate between mutant and wild type alleles presents
the same advantages in the ﬁeld of oncology as it does for
the dominant mutant neurodegenerative disorders discussed
above. Multiple oncogenic gene fusions formed by chromo-
somal translocation in leukemia and lymphoma have been
readily inhibited by RNAi approaches in vitro (reviewed in
6002 S.L. Uprichard / FEBS Letters 579 (2005) 5996–6007[144]), while more stringent allele-speciﬁc targeting has been
achieved for several single nucleotide mutant forms of ras
and p53, which are both prevalent in human cancers
[12,89,158,159].
Drug sensitization. Although direct inhibition of an onco-
gene may slow tumor growth, it does not eliminate the cancer-
ous cells. Furthermore, reducing the rate of tumor cell
proliferation might be expected to reduce the eﬀectiveness of
traditional therapies that preferentially target actively dividing
cells. Hence, the potential use of RNAi to facilitate the eﬀects
of traditional cancer therapeutics has been proposed. For
example, targeted suppression of the anti-apoptotic bcl-2 gene
sensitizes cells to chemotherapy agents, such as etopodise and
daunorubicin [158,160,161]. Likewise, siRNA silencing of dou-
ble-strand break repair proteins, such as the DNA-dependent
protein kinase catalytic subunit, confer enhanced radio and
chemosensitivity to tumor cells [162,163]. RNAi might also
complement chemotherapy in the treatment of patients that
have developed multidrug resistance. While over 30% of cancer
patients develop resistance to chemotherapeutic agents due to
an over expression of the multidrug resistance gene (MDR1)
[164], RNAi-mediated suppression of MDR1 has been shown
to re-sensitize cells to the eﬀects of chemotherapy [165,166].
Hence, if RNAi eﬀectors could be speciﬁcally delivered to
tumors, these cells could be made preferentially sensitive to
traditional cancer therapies.
Inhibition of invasion and migration. Finally, another cancer
treatment approach being investigated is the use of RNAi to
indirectly control tumor growth by inhibition of processes re-
quired for tumor spread. For example, in the case of breast
cancer, transformed cells express the chemokine receptor
CXCR4, which promotes metastasis to organs abundant in
CXCR4 ligand [167]. Several groups have shown RNAi-med-
iated inhibition of CXCR4 results in reduced cell invasion
in vitro, as well as a block in breast cancer metastasis in xeno-
graph animal models [146,167,168]. As a more general ap-
proach, members of the vascular endothelial growth factor
(VEGF) family, which are involved in the generation of new
blood vessels required for tumor growth, are being tested as
a potential anti-cancer treatment targets (reviewed in [169]).
After transplanting tumor cells subcutaneously into mice,
two groups have shown that intratumoral injections of
VEGF-speciﬁc siRNAs, either naked or complexed with atelo-
collagen, blocked angiogenesis and limited tumor growth
[156,170]. More recently, Schiﬀelers et al. [46] achieved similar
results delivering VEGF receptor-speciﬁc siRNAs to xeno-
graph tumors by intravenous injection of ligand-targeted, sta-
bilized nanoparticles.4.4. Ocular disease
Angiogenesis additionally has a causal role in several ocu-
lar diseases including age-related macular degeneration
(AMD), herpetic stromal keratitis, and diabetic retinopathy
[171]. VEGF has been found to be directly involved in the
destructive vascularization associated with these ocular dis-
ease. The ability of VEGF-speciﬁc siRNAs to reduce
VEGF-dependent vascular invasion of the eye has not only
been demonstrated in animal models [130,131] (Table 3),
but phase I AMD clinical trials in patients is ongoing as well
[34]. Notably, however, there is a competing technology in
this area, as an anti-VEGF aptamer therapeutic, Pegaptanibsodium, was approved for the treatment of AMD in Decem-
ber 2004 [172].4.5. Inﬂammation and apoptosis
In some diseases, the pathology observed is caused by the
activation of innate cellular processes. Hence, by targeting
key molecules involved in these pathways, RNAi therapeu-
tics may provide a means of controlling the cellular pro-
cesses responsible. For example, tumor necrosis factor
(TNF)a is a proinﬂammatory cytokine involved in the
chronic pathogenesis of rheumatoid arthritis (RA). While
drugs currently being used to block the action of TNFa
have been shown to be eﬀective in reducing inﬂammation
and slowing RA progression, several risks, such as conges-
tive heart failure, demyelinating diseases, systemic lupus ery-
thematosus, lymphoma, and serious infections, have been
associated with the use of systemic TNFa-blockers [173].
In a preclinical mouse model of collagen induced arthritis,
Schiﬀelers and colleagues recently demonstrated that local
injection and electroporation of TNFa-speciﬁc siRNAs eﬀec-
tively inhibited paw inﬂammation in mice [133]. Further-
more, using an intravenously injected luciferase reporter,
the authors subsequently showed that joint injection and
electroporation of luciferase-speciﬁc siRNAs only inhibited
the reporter gene locally. These studies suggest that in lieu
of conventional anti-TNFa blockers, local delivery of
TNFa-speciﬁc siRNAs might provide a safer means of
reducing inﬂammation in RA patients.
While many proposed RNAi therapeutic targets are related
to chronic and/or progressive diseases, it is important to note
that RNAi could also potentially serve a valuable function in
limiting acute responses as well. In a mouse model of sepsis,
it has been shown that pretreatment with TNFa-speciﬁc siR-
NAs injected intraperitoneally was able to increase survival
rate sixfold after lethal lipopolysaccharide challenge [44]. Sim-
ilarly, one of the ﬁrst experiments to demonstrate the thera-
peutic potential of RNAi used fas-speciﬁc siRNAs to protect
mice against fulminant hepatitis [134], and another study re-
ported that caspase 8-speciﬁc siRNA treatment also prevented
acute liver failure [135]. These studies illustrate the concept
that siRNAs might be used eﬀectively to control acute re-
sponses whether that means limiting dangerous, uncontrolled
inﬂammation or preventing hepatocyte apoptosis and preserv-
ing liver function (Table 3).5. Conclusion
Although not complete, the above list of potential therapeu-
tic applications of RNAi is intended to illustrate how the
advantages inherent in RNAi technology (Speciﬁcity, Potency,
and Versatility) could possibly translate into signiﬁcant pro-
gress in molecular medicine. However, it is important to also
revisit the sobering challenges that face all sequence-speciﬁc
gene silencing technologies (Delivery, Safety, and Eﬃcacy) be-
fore making any predictions about the future of this promis-
ing, yet immature, technology. Fortuitously, the development
of RNAi technology has been facilitated by the many years
of previous research into antisense drug delivery and the enor-
mous amount of genetic information recently obtained from
the Human Genome Project. With the convergence of all these
S.L. Uprichard / FEBS Letters 579 (2005) 5996–6007 6003events, momentum alone seems to be providing the extra push
that could make a leap forward possible.
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